Abstract: The invention relates to a recombinant adenovirus that has an oncolytic effect in a cancer cell. By modulating the level and type of splice isoforms of the E1B gene product, expressed from the E1B gene, the oncolytic activity of such viruses can be enhanced. The invention provides a recombinant adenovirus in which the proportion of the E1B-156R isoform is increased relative to wild-type levels. Such a recombinant adenovirus may selectivity replicate in cancer cells, thereby killing cancer cells while sparing normal cells.
Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.
Abstract: The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
Abstract: The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
July 24, 2018
Assignee:
INSTITUTO NACIONAL DE TECHNOLOGÍA AGROPECUARIA
Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
Type:
Grant
Filed:
March 20, 2017
Date of Patent:
July 24, 2018
Assignee:
Trellis Bioscience, LLC
Inventors:
Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
Abstract: The present invention relates to the discovery that measurement of the level of cytochrome c (Cyt-C) in the plasma can be used as a diagnostic signature to predict antiretroviral therapy (ART) toxicity in human immunodeficiency virus (HIV) infected patients. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a HIV patient with ART toxicity, methods of predicting a patient's risk of having or developing toxicity for ART, methods of assessing if a patient will benefit from a change in the treatment strategies by adjusting the dosage and/or changing the medication or even terminating of ART, and methods of predicting antiretroviral drugs propensity for causing mitochondrial toxicity. Furthermore, the invention encompasses a diagnostic kit for carrying out the aforementioned methods.
Abstract: Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
Type:
Grant
Filed:
September 30, 2014
Date of Patent:
July 3, 2018
Assignees:
Los Alamos National Security, LLC, Oxford University Innovation Limited
Inventors:
Bette T. M. Korber, Tomas Hanke, Andrew McMichael
Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are polynucleotides encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
June 26, 2018
Assignee:
JANSSEN VACCINES & PREVENTION B.V.
Inventors:
Edward N. van den Brink, Cornelis A. de Kruif, Mark Throsby
Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.
Type:
Grant
Filed:
June 23, 2016
Date of Patent:
June 26, 2018
Assignees:
Massachusetts Institute of Technology, Lahey Clinic Foundation, Inc.
Inventors:
Michael J. Cima, Gregory J. Ekchian, Christophoros C. Vassiliou, Vincent H. Liu, Christoph Wald, Sebastian Flacke, Fredric D. Gordon
Abstract: The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
Type:
Grant
Filed:
December 31, 2015
Date of Patent:
June 26, 2018
Assignees:
WASHINGTON STATE UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).
Type:
Grant
Filed:
September 12, 2013
Date of Patent:
June 26, 2018
Assignees:
Duke University, Los Alamos National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer, The Board of Trustees of the Leland Stanford Junior University
Inventors:
Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John Mascola
Abstract: The present invention relates to a use of a protein nanoparticle-based hydrogel, and more particularly, to a use of a protein nanoparticle-based hydrogel capable of highly sensitive and simultaneous multi-detection of disease markers by using a hydrogel within which protein nanoparticles presenting multiple copies of disease marker detection probes are immobilized.
Type:
Grant
Filed:
May 11, 2016
Date of Patent:
June 19, 2018
Assignee:
KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Inventors:
Jeewon Lee, Eun Jung Lee, Jong Hwan Lee
Abstract: The present invention concerns methods and compositions for treatment of HIV infection using a T20 expression vector, such as that shown in SEQ ID NO:1 or SEQ ID NO:3. The T20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to HIV, localized transfection in vivo in a gene therapy approach to provide longer term delivery of T20, or in vitro production of T20 peptide. The T20 may be secreted into the circulation to act as a fusion inhibitor of HIV infection, or may induce an endogenous immune response to HIV or HIV-infected cells. Alternatively, a DDD peptide may be incorporated in a fusion protein comprising T20 or another antigenic protein or peptide to enhance the immune response to the protein or peptide.
Type:
Grant
Filed:
May 16, 2017
Date of Patent:
June 12, 2018
Assignee:
Immunomedics, Inc.
Inventors:
Sofia Stenler, Britta Wahren, Chien-Hsing Chang, David M. Goldenberg
Abstract: Dual variable domain immunoglobulins (DVD Igs) are provided capable of tetravalent binding to bispecific sites of the human immunodeficiency virus (HIV). The DVD Igs may be asymmetric and may have more variable domains on either the light chain or the heavy chain of the Igs. The DVD Igs may have specificity for gp41 and gp120. Therapies are provided using DVD Igs to neutralize HIV viral loads.
Type:
Grant
Filed:
July 23, 2014
Date of Patent:
June 5, 2018
Assignee:
Board of Supervisor of Louisiana State University and Agricultural and Mechanical College
Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens.
Type:
Grant
Filed:
January 28, 2013
Date of Patent:
June 5, 2018
Assignees:
Laboratories Del Dr. Esteve S.A., Fundació Privada Institut De Recerca De La Sida—CAIXA
Inventors:
Christian Brander, Beatriz Mothe Pujadas, Anuska Llano
Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
Type:
Grant
Filed:
November 1, 2012
Date of Patent:
June 5, 2018
Assignee:
SENTINEXT THERAPEUTICS Sdn Bhd
Inventors:
Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
Abstract: The invention provides a construct containing two or more monomeric griffithsin molecules, optionally joined by a linker, as well as conjugate comprising the construct, a nucleic acid encoding the construct or conjugate, vectors, and cells. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.
Type:
Grant
Filed:
June 5, 2014
Date of Patent:
May 29, 2018
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Barry R. O'Keefe, Alexander Wlodawer, Tinoush Moulaei
Abstract: A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
June 6, 2014
Date of Patent:
May 22, 2018
Assignees:
VIROXIS SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SUD XI